Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00820404 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Single Doses of BLI-489 in Healthy Subjects
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT00820404 is a Phase 1 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 54 participants.
The verdict
NCT00820404, a Phase 1 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, and tolerability of single doses of BLI-489 administered intravenously in healthy subjects, and also how the drug is absorbed and eliminated.
Interventions
- DRUG Placebo
- DRUG BLI-489
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00820404
The ClinicalTrials.gov registry entry for NCT00820404 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00820404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00820404 about?
NCT00820404 is a clinical study titled "Study Evaluating Single Doses of BLI-489 in Healthy Subjects". The purpose of this study is to evaluate the safety, and tolerability of single doses of BLI-489 administered intravenously in healthy subjects, and also how the drug is absorbed and eliminated.
What is the current status of trial NCT00820404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2009-01. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00820404?
The interventions under investigation include: Placebo (DRUG), BLI-489 (DRUG).
Who is sponsoring clinical trial NCT00820404?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.